<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82984">
  <stage>Registered</stage>
  <submitdate>15/07/2008</submitdate>
  <approvaldate>30/07/2008</approvaldate>
  <actrnumber>ACTRN12608000369325</actrnumber>
  <trial_identification>
    <studytitle>Micropulse laser treatment study</studytitle>
    <scientifictitle>In patients with Diabetic Maculopathy, is micropulse laser treatment, better than argon laser treatment, at improving or stabilising visual acuity and reducing retinal oedema?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Maculopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Micropulse laser, single treatment, via slit-lamp microscope.
One eye with condition to be treated.
The radiant exposure of the laser will be 70 - 120mJ/cm2 per treatment spot. 
Treatment duration 10 to 30 minutes.
Overall intervention period will be 1yr.</interventions>
    <comparator>Argon laser, single treatment, via slit-lamp microscope.
Treatment duration 10 to 30 minutes.
The radiant exposure of the laser will be 16 - 250J/cm2 per treatment spot.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Improvement or stabilisation of visual acuity</outcome>
      <timepoint>Baseline testing pre treatment, with 3 and 6 month follow-up testing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in retinal oedema measured by OCT (Optical Coherance Tomography) retinal thickness.</outcome>
      <timepoint>Baseline testing pre treatment, with follow-up testing at 3 and 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes
Focal or diffuse macular oedema</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous laser treatment
Proliferative retinopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Simple randomisation by shuffling of envelopes</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>23/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ellex R&amp;D Pty Ltd</primarysponsorname>
    <primarysponsoraddress>82 Gilbert Street, Adelaide, South Australia, 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ellex R&amp;D Pty Ltd</fundingname>
      <fundingaddress>82 Gilbert Street, Adelaide, South Australia, 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Royal Adelaide Hospital</othercollaboratorname>
      <othercollaboratoraddress>1 North Terrace, Adelaide, South Australia, 5000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to determine if in patients with Diabetic Maculopathy micropulse laser treatment is better than argon laser treatment, at improving or stabilising visual acuity and reducing retinal oedema.
The hypothesis is that the micropulse laser may provide as good or better therapeutic benefit as compared to current treatments but without the damage normally associated with this treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Research Ethics Committee, Royal Adelaide Hospital</ethicname>
      <ethicaddress>Level 3, Hanson Institute, 1 North Terrace, Adelaide, South Australia, 5000</ethicaddress>
      <ethicapprovaldate>18/03/2008</ethicapprovaldate>
      <hrec>071123a</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>malcolm plunkett</name>
      <address>82 Gilbert Street, Adelaide, South Australia, 5000</address>
      <phone>08 81045200</phone>
      <fax />
      <email>mplunkett@ellex.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>malcolm plunkett</name>
      <address>82 Gilbert Street, Adelaide, South Australia, 5000</address>
      <phone>08 81045200</phone>
      <fax />
      <email>mplunkett@ellex.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>